Goldman Sachs’s Ginkgo Bioworks DNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
– Sell
-3,000
Closed -$203K – 5983
2022
Q4
$203K Buy
+3,000
New +$276K ﹤0.01% 5300

Other funds holding DNA

Goldman Sachs's DNA Position: Q2 2026 in Review

Goldman Sachs reduced its Ginkgo Bioworks (DNA) stake by 35% in Q2 2026, selling an estimated $2.7M and leaving 607,376 shares worth $6.02M. The position accounts for ﹤0.01% of the portfolio, ranked #3714.

Goldman Sachs first reported a position in DNA in Q1 2022 and has held it in 18 quarters since. The position peaked at $12.9M in Q2 2025. 183 funds tracked by Wall St. Rank hold DNA as of Q2 2026.

  • Goldman Sachs held 607,376 shares of Ginkgo Bioworks worth $6.02M as of Q2 2026.
  • Goldman Sachs sold 322,486 Ginkgo Bioworks shares in Q2 2026, an estimated $2.7M.
  • Ginkgo Bioworks made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #3714 holding.
  • Goldman Sachs first reported a position in Ginkgo Bioworks in Q1 2022 and has held it in 18 quarters since.
  • Goldman Sachs's Ginkgo Bioworks position peaked at $12.9M in Q2 2025.
  • 183 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.